R-954, a bradykinin B1 receptor antagonist, as a potential therapy in a preclinical endometriosis model
article
OA: closed
CC0
⤵ 2 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
R-954, a bradykinin B1 receptor antagonist, demonstrated therapeutic potential in a preclinical model of endometriosis by reducing disease severity.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (42)
- Bradykinin system is involved in endometriosis‐related pain through endothelin‐1 production via openalex
- Current and Emerging Therapeutics for the Management of Endometriosis via openalex
- Endometriosis and Infertility via openalex
- Endometriosis: current challenges in modeling a multifactorial disease of unknown etiology via openalex
- Endometriosis in MRKH cases as a proof for the coelomic metaplasia hypothesis? via openalex
- Endometriosis: pathogenesis and treatment via openalex
- Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy via openalex
- Increased levels of human neutrophil peptides 1, 2, and 3 in peritoneal fluid of patients with endometriosis: association with neutrophils, T cells and IL-8 via openalex
- Inflammation to Infertility: Panoramic View on Endometriosis via openalex
- Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue via openalex
- Neutrophil depletion reduces endometriotic lesion formation in mice via openalex
- NK Cells as Potential Targets for Immunotherapy in Endometriosis via openalex
- Pro-endometriotic niche in endometriosis via openalex
- Progesterone Alleviates Endometriosis via Inhibition of Uterine Cell Proliferation, Inflammation and Angiogenesis in an Immunocompetent Mouse Model via openalex
- Rethinking mechanisms, diagnosis and management of endometriosis via openalex
- The link between immunity, autoimmunity and endometriosis: a literature update via openalex
- The Origin and Pathogenesis of Endometriosis via openalex
- W2409717932 via openalex
- W2765750028 via openalex
- W2997403676 via openalex
- W6644015818 via openalex
- W6666980266 via openalex
- W6728658130 via openalex
- W6752006272 via openalex
- W6785657983 via openalex
- W6786837891 via openalex
- W1964380344 via openalex
- W1967132326 via openalex
- W1999536790 via openalex
- W2005098530 via openalex
- W2051026900 via openalex
- W2076786251 via openalex
- W2082360357 via openalex
- W2090131666 via openalex
- W2122274157 via openalex
- W2135892502 via openalex
- W2169530240 via openalex
- W2182674165 via openalex
- W2313533844 via openalex
- W2316125911 via openalex
- W2332205625 via openalex
- W2346020725 via openalex
Cited by (2)
- Preconceptional immunomodulation partially corrects pregnancy abnormalities induced by endometriosis in a mouse model, with normalization of transcriptional alterations observed in the developing fetal-maternal interface at the single cell level 2026
- Precision Therapeutic and Preventive Molecular Strategies for Endometriosis-Associated Infertility 2025
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-06-04T00:32:28.536610+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK